Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing
Description
Author discusses the question, "Will outsourcing determination of antibiotic effectiveness allow drug companies to influence prescribing?"Citation
Doshi, P. (2016). Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. BMJ, 352. DOI: 10.1136/bmj.h6849Keyword
National Physicians Alliance FDA Task Force21st Century Cures Act
Clinical and Laboratory Standards Institute
United States. Food and Drug Administration
Conflict of Interest
Microbial Sensitivity Tests--standards
Outsourced Services--standards
Identifier to cite or link to this item
http://hdl.handle.net/10713/6584ae974a485f413a2113503eed53cd6c53
10.1136/bmj.h6849
Scopus Count
Collections
Related articles
- The determinants of policy effectiveness.
- Authors: Potter CC, Harries J
- Issue date: 2006 Nov
- Keys to healthcare outsourcing success.
- Authors: Klein SR
- Issue date: 2006 Winter
- Regulating compounding pharmacies.
- Authors: Noble A
- Issue date: 2015 Jun
- Could State Regulations be the Next Frontier in Preemption Jurisprudence? Drug Compounding as a Case Study.
- Authors: Brown NA, Tomar E
- Issue date: 2016
- Analysis of factors influencing antibiotic usage in hospitals.
- Authors: Sabath LD, Notto DA
- Issue date: 1979